Literature DB >> 22456614

Development of hepatitis C virus production reporter-assay systems using two different hepatoma cell lines.

Midori Takeda1, Masanori Ikeda1, Yasuo Ariumi1, Takaji Wakita2, Nobuyuki Kato1.   

Abstract

A hepatitis C virus (HCV) infection system was developed previously using the HCV JFH-1 strain (genotype 2a) and HuH-7 cells, and this cell culture is so far the only robust production system for HCV. In patients with chronic hepatitis C, the virological effects of pegylated interferon and ribavirin therapy differ depending on the HCV strain and the genetic background of the host. Recently, we reported the hepatoma-derived Li23 cell line, in which the JFH-1 life cycle is reproduced at a level almost equal to that in HuH-7-derived RSc cells. To monitor the HCV life cycle more easily, we here developed JFH-1 reporter-assay systems using both HuH-7- and Li23-derived cell lines. To identify any genetic mutations by long-term cell culture, HCV RNAs in HuH-7 cells were amplified 130 days after infection and subjected to sequence analysis to find adaptive mutation(s) for robust virus replication. We identified two mutations, H2505Q and V2995L, in the NS5B region. V2995L but not H2505Q enhanced JFH-1 RNA replication. However, we found that H2505Q but not V2995L enhanced HCV RNA replication of strain O (genotype 1b). We also selected highly permissive D7 cells by serial subcloning of Li23 cells. The expression levels of claudin-1 and Niemann-Pick C1-like 1 in D7 cells are higher than those in parental Li23 cells. In this study, we developed HCV JFH-1 reporter-assay systems using two distinct hepatoma cell lines, HuH-7 and Li23. The mutations in NS5B resulted in different effects on strains O and JFH-1 HCV RNA replication.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22456614     DOI: 10.1099/vir.0.040725-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Raloxifene inhibits hepatitis C virus infection and replication.

Authors:  Midori Takeda; Masanori Ikeda; Kyoko Mori; Masahiko Yano; Yasuo Ariumi; Hiromichi Dansako; Takaji Wakita; Nobuyuki Kato
Journal:  FEBS Open Bio       Date:  2012-08-22       Impact factor: 2.693

2.  New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.

Authors:  Youki Ueda; Midori Takeda; Kyoko Mori; Hiromichi Dansako; Takaji Wakita; Hye-Sook Kim; Akira Sato; Yusuke Wataya; Masanori Ikeda; Nobuyuki Kato
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

3.  Hepatitis C Virus Resistance to Carbohydrate-Binding Agents.

Authors:  Laure Izquierdo; Catarina Oliveira; Carole Fournier; Véronique Descamps; Virginie Morel; Jean Dubuisson; Etienne Brochot; Catherine Francois; Sandrine Castelain; Gilles Duverlie; Francois Helle
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

4.  A subclone of HuH-7 with enhanced intracellular hepatitis C virus production and evasion of virus related-cell cycle arrest.

Authors:  Asako Murayama; Nao Sugiyama; Seiko Yoshimura; Mitsuko Ishihara-Sugano; Takahiro Masaki; Sulyi Kim; Takaji Wakita; Shunji Mishiro; Takanobu Kato
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

5.  Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus.

Authors:  Francois Helle; Etienne Brochot; Carole Fournier; Véronique Descamps; Laure Izquierdo; Thomas W Hoffmann; Virginie Morel; Yves-Edouard Herpe; Abderrahmane Bengrine; Sandrine Belouzard; Czeslaw Wychowski; Jean Dubuisson; Catherine Francois; Jean-Marc Regimbeau; Sandrine Castelain; Gilles Duverlie
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

6.  Genetic characterization of hepatitis C virus in long-term RNA replication using Li23 cell culture systems.

Authors:  Nobuyuki Kato; Hiroe Sejima; Youki Ueda; Kyoko Mori; Shinya Satoh; Hiromichi Dansako; Masanori Ikeda
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.